Penumbra, Inc. PEN
Penumbra is a commoditized single-product 510(k) company whose aspiration-catheter franchise is collapsing to deep-pocketed bundlers; Spruce Point sees 40-55% downside to $85-110 per share.
Thesis
Penumbra pioneered neurovascular aspiration catheters for acute ischemic stroke, but the product is a low-tech, undifferentiated plastic consumable cleared only through the 510(k) pathway. Spruce Point obtained proprietary IQVIA Medical Device & Supply Audit data showing that since September 2018 Penumbra's monthly U.S. neuro aspiration-catheter unit sales have declined YoY by up to 28%, even as the mechanical thrombectomy market grows 20-40%. Medtronic (React 68/71), Stryker (Vecta/Jet7), Terumo (Sofia) and J&J/Cerenovus have entered the vertical and bundle aspiration catheters aggressively with stent retrievers. Physician interviews corroborate a shift from near-100% Penumbra usage to 0-30% within nine months. Yet PEN trades at 11.3x FY19 EV/Sales on par with PMA peers despite weaker IP, only 8% R&D intensity and aggressive insider selling. A 5-6.5x multiple on cut growth implies $85-110 per share, 40-55% below $179.49.
SCQA
Penumbra is a single-product medical-device company that pioneered aspiration catheters for acute ischemic stroke and trades at roughly $179, valued as a premium high-growth medtech with ~20% forecast sales growth.
Medtronic, Stryker, Terumo and J&J/Cerenovus have launched superior bundled aspiration catheters; IQVIA transaction data and neurosurgeon interviews show Penumbra's U.S. neuro-AC unit sales turning negative YoY while the broader thrombectomy market grows 20-40%.
Investors should cut FY19-21 Penumbra sales growth to about 10-13%, roughly half of consensus, and rerate the stock from 10x to a 510(k)-appropriate 5-6.5x EV/Sales multiple consistent with commoditized-device peers.
Spruce Point estimates 40-55% downside to a $85-$110 share price, with a bull case at $110.81 (-38.4%) and bear case at $84.35 (-53.1%) versus the current $179.49.
The three reasons
- 1
IQVIA hospital data: PEN neuro aspiration-catheter unit sales turned negative YoY while thrombectomy market grows 20-40%
- 2
Medtronic React 68/71, Stryker, Terumo and J&J/Cerenovus entered the AC market and bundle it cheaply against stent retrievers
- 3
PEN trades at 11.3x FY19 EV/Sales like PMA peers despite weak 510(k) IP, 8% R&D and heavy insider selling
Primary demands
- Investors should sell Penumbra shares
- Street should cut FY19-21 sales growth estimates roughly in half
- PEN multiple should rerate from PMA-tier ~10x to 510(k)-appropriate 5-6.5x EV/Sales
KPIs cited
Pattern membership
Precedents cited
- iRobot (Spruce Point Nov 2018 / Mar 2019 short)
- Maxar Technologies (Spruce Point Aug 2018 short)
- Bazaarvoice (Spruce Point May 2012 short)
- MR CLEAN, ESCAPE, SWIFT PRIME, EXTEND-IA, REVASCAT stent-retriever trials
Composition what's on the 61 slides
Slide gallery ·
Notes
Short-seller research report titled 'Sucking Wind' with Strong Sell opinion. Argues competitive collapse, not accounting fraud — thesis_types includes fraud_exposure only because the genre is a short report; the substance is multiple-rerating plus promotional-management critique (hallmark Spruce Point pattern). Leans heavily on proprietary IQVIA MDSA hospital transaction data and ~5 neurosurgeon channel checks as the differentiated evidence base. Cover slide (surgeons operating on a 'market share report' body with a rat on the equipment, under a 'strong sell' banner) is the only stylistically distinctive visual — rest of the deck is standard Spruce Point template (teal/grey palette, dense data tables). Stake not disclosed beyond 'short position' boilerplate. No individual Penumbra executive is named as villain; critique stays at 'management' level. Ben Axler is firm founder but no personal signature on the deck — author_name left null.